Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
D053302:Apolipoprotein C-I; D053304:Apolipoprotein C-II; D001053:Apolipoproteins / Q000097:blood; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D011487:Protein Conformation; D014280:Triglycerides / Q000097:blood
D053302:Apolipoprotein C-I; D053304:Apolipoprotein C-II; D001053:Apolipoproteins; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D000960:Hypolipidemic Agents; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate